Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine and Alemtuzumab in Pretreated CLL
NCT00951457Phase 2Completed
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- Mar 2009
- Primary completion
- Aug 2012
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine and alemtuzumab in chronic lymphocytic leukemia (CLL), sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Primary endpoint: Percentage of patients achieving a response at 16 months. Started Mar 2009; status: completed.
02
Drugs
bendamustinealemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00951457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00951457.